Advertisement

Bradykinin and Cardiac Protection

  • Peter Gohlke
  • Carsten Tschöpe
  • Thomas Unger
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 432)

Abstract

Administration of bradykinin to humans and several animal species engenders a variety of effects, including blood pressure reduction through endothelium-dependent vasorelaxation, changes in renal blood flow and tubular function, inflammatory reactions, vasoconstriction via direct effects on smooth muscle cells, alteration in vascular permeability and activation of sensory pain fibres1–3. Since circulating concentrations of bradykinin are usually too low to cause systemic effects4,5, autocrine and paracrine actions of kinins have increasingly received scientific attention.

Keywords

Angiotensin Converting Enzyme Infarct Size Myocardial Blood Flow Angiotensin Converting Enzyme Inhibition Cardiac Protection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bhoola KD, Figuero CD, Worthy K: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44(1): 1–80PubMedGoogle Scholar
  2. 2.
    Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25–49PubMedGoogle Scholar
  3. 3.
    Margolius HS: Kallikreins and kinins. Molecular characteristics and cellular and tissue responses. Diabetes 1996;45(Suppl. 1):S14–S19PubMedGoogle Scholar
  4. 4.
    Scicli AG, Mindrooiu T, Scicli G, Carretero OA: Blood kinins their concentrations in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin 1982;100:81–93Google Scholar
  5. 5.
    Shimamoto K, Ando T, Tanaka S, Nakahashi Y, Nishitani T, Hosoda S, Ishida H, Iimura O: An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. Endocrinol Jpn 1982;29:487–494PubMedCrossRefGoogle Scholar
  6. 6.
    Ryan JW, Robelero J, Stewart JM: Inactivation of bradykinin in the pulmonary circulation. Biochem J 1986;110:795–797Google Scholar
  7. 7.
    Farhy RD, Carretero OA, Ho K-L, Scicli AG: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993;72: 1202–1210PubMedCrossRefGoogle Scholar
  8. 8.
    Becker RHA, Wiemer G, Linz W: Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18(suppl. 2):S110–S115PubMedGoogle Scholar
  9. 9.
    Schülkens BA, Linz W, König W: Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist. J Hypertens 1988;(suppl. 4):S25–S28Google Scholar
  10. 10.
    Danieli HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ: Effects of Captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984;6:1043–1047Google Scholar
  11. 11.
    Ertl G: Angiotensin converting enzyme inhibitors and ischemic heart disease. Eur Heart J 1988;9:716–727PubMedCrossRefGoogle Scholar
  12. 12.
    Kass RW, Kotier MN, Yazdanfar S: Stimulation of coronary collateral growth: current developments in angiogenesis and future clinical applications. Am Heart J 1992; 123(2):486–496PubMedCrossRefGoogle Scholar
  13. 13.
    Lefer AM, Peck RC: Cardioprotective effects of enalapril in acute myocardial ischemia. Pharmacol 1984; 29:61–69CrossRefGoogle Scholar
  14. 14.
    Hock CE, Ribeiro GT, Lefer AM: Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985;109:222–228PubMedCrossRefGoogle Scholar
  15. 15.
    Stauss HM, Zhu YC, Redlich T, Unger T: Early and late treatment of infarction-induced heart failure with a converting enzyme inhibitor: Bradykinin potentiation versus angiotensin II reduction. Hypertension 1993;22(3):429(abstract)Google Scholar
  16. 16.
    Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel KC, Unger T: ACE inhibition in infarct-induced heart failure. bradykinin versus angiotensin II. J Cardiovasc Risk 1994;1:255–262PubMedGoogle Scholar
  17. 17.
    Stauss HM, Zhu YC, Redlich T, Adamiak D, Moot A, Unger T: Mechanism involved in the reduction of infarct size by ACE inhibition after left coronary ligation in rats. J Hypertens 1994; 12(suppl 13):S2 (abstract)Google Scholar
  18. 18.
    Duncan AM, Burell LM, Kladis A, Campbell DJ: Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Phamacol 1996; 28:746–754CrossRefGoogle Scholar
  19. 19.
    Linz W, Schölkens BA: A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771–772PubMedCrossRefGoogle Scholar
  20. 20.
    Gohlke P, Linz W, Schülkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T: Angiotensin converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension 1994;23:411–418PubMedCrossRefGoogle Scholar
  21. 21.
    Unger T, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Schölkens BA, Gohlke P: Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 1992;20:478–482PubMedCrossRefGoogle Scholar
  22. 22.
    Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T: Bradykinin B2-receptor blockade prevents the increase in capillary growth density induced by chronic ACE inhibitor treatment in SHRSP. Hypertension 1997;29:478–482PubMedCrossRefGoogle Scholar
  23. 23.
    Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG: A local kallikrein-kinin system is present in rat hearts. Hypertension 1994;23(2):919–923PubMedCrossRefGoogle Scholar
  24. 24.
    Campbell DJ, Kladis A, Duncan A-M: Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 1993;21:155–165PubMedCrossRefGoogle Scholar
  25. 25.
    Maeceau F: Kinin Bl receptors: a review. Immunopharmacol 1995;30(1):1–26CrossRefGoogle Scholar
  26. 26.
    Vavrek RJ, Stewart JM: Competitive antagonists of bradykinin. Peptides 1985;6:161–164PubMedCrossRefGoogle Scholar
  27. 27.
    Bao G, Qadri F, Stauss B, Stauss H, Gohlke P, Unger T: HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur J Pharmacol 1992;200:179–182CrossRefGoogle Scholar
  28. 28.
    Hock FJ, Wirth K, Linz W, Gerhards HJ, Wiemer G, Henke ST, Breipohl G, König W, Knolle J, Schölkens BA: Hoe 140 a new potent and long acting bradykinin-antagonist: In vitro studies. Br J Pharmacol 1991; 102:769–773PubMedCrossRefGoogle Scholar
  29. 29.
    Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke St, Breipohl G, König W, Knolle J, Schölkens BA: Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991;102:774–777PubMedCrossRefGoogle Scholar
  30. 30.
    Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Linz W, Schölkens BA, Wiemer G, Unger T: Longterm low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3’,5’-monophosphate. Hypertension 1993;22:682–687PubMedCrossRefGoogle Scholar
  31. 31.
    Bao G, Gohlke P, Qadri F, Unger T: Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992;20:74–79PubMedCrossRefGoogle Scholar
  32. 32.
    Fabris B, Jackson B, Kanazawa M, Johnston CI: Increased cardiac ACE in rats with chronic heart failure. Clin Exp Pharmacol Physiol 1990; 17:309–314PubMedCrossRefGoogle Scholar
  33. 33.
    Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein AT, Apstein CS, Lorell BH: Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest 1990;86:1913–1920PubMedCrossRefGoogle Scholar
  34. 34.
    Falkenhahn M, Franke F, Bohle RM, Zhu Y, Stauss HM, Bachmann S, Danilov S, Unger T: Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 1995;25:219–226PubMedCrossRefGoogle Scholar
  35. 35.
    Liang CS, Gavras H, Black J, Sherman LG, Hood WB: Renin-angiotensin system inhibition in acute myocardial infarction in dogs: effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation 1982;66:1249–1255PubMedCrossRefGoogle Scholar
  36. 36.
    Brown EJ, Swinfor RD, Shatkin BJ, Honig SC, Cohn PF: Massive reperfusion injury: paradoxical effect of combined angiotensin-converting enzyme inhibition plus myocardial perfusion. J Am Coll Cardiol 1988; 11:50ACrossRefGoogle Scholar
  37. 37.
    De Lorgeril M, Ovize M, Delaye G, Renaud S: Importance of the flow perfusion deficit in the response to Captopril in experimental myocardial infarction. J Cardiovasc Pharmacol 1992; 19:324–325PubMedCrossRefGoogle Scholar
  38. 38.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828Google Scholar
  39. 39.
    Trandopril Cardiac Evaluation (TRACE) Study group: A clinical trial of the angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl Med 1995;333(25): 1670–1676CrossRefGoogle Scholar
  40. 40.
    Hashimoto K, Hirose M, Furukawa S, Hayakawa H, Kimura E: Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary occlusion. Jpn Heart J 1977;18:679–689PubMedCrossRefGoogle Scholar
  41. 41.
    Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G: Ramiprilat increases bradykinin outflow from isolated rat hearts. Br J Pharmacol 1993;108:293–295PubMedCrossRefGoogle Scholar
  42. 42.
    Lamontagne D, Nadeau R, Adam A: Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischaemic rat heart. Br J Pharmacol 1995; 115:476–478PubMedCrossRefGoogle Scholar
  43. 43.
    Lamontagne D, Nakhostine N, Couture R, Nadeau R: Mechanism of kinin B1-receptor-induced hypotension in the anesthetized dog. J Cardiovasc Pharmacol 1996;28:645–650PubMedCrossRefGoogle Scholar
  44. 44.
    Rosas R, Montague D, Gross M, Bohr DF: Cardiac action of vasoactive polypeptides in the rat. Circ Res 1965;16:150–161PubMedCrossRefGoogle Scholar
  45. 45.
    Groves P, Kurz S, Just H, Drexler H: Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995;92:3424–3430PubMedCrossRefGoogle Scholar
  46. 46.
    Linz W, Schülkens BA, Han YF: Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol 1986;8(suppl. 10):S91–S99PubMedCrossRefGoogle Scholar
  47. 47.
    Van Gilst WH, De Graeff PA, Leeuw MJ, Scholtens E, Wesseling H: Converting enzyme inhibitors and the role of their sulfhydryl group in the potentiation of exo-and endogenous nitrovasodialtors. J Cardiovasc Pharmacol 1991;18:429–436PubMedCrossRefGoogle Scholar
  48. 48.
    Ertl G, Kloner RA, Alexander RW, Braunwald E: Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40–48PubMedCrossRefGoogle Scholar
  49. 49.
    Przyklenk K, Kloner RA: Cardioprotection by ACE-inhibitors in acute myocardial ischemia and infarction?. Basic Res Cardiol 1993;88(Suppl 1):139–154PubMedGoogle Scholar
  50. 50.
    Smits JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP: Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 1992;20:772–778PubMedGoogle Scholar
  51. 51.
    Raya TE, Fonken SJ, Lee RW, Daugherty S, Goldman S, Wong PC, Timmermans PB, Morkin E: Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model for heart failure. Am J Hypertens 1991;4:334S–340SPubMedGoogle Scholar
  52. 52.
    Spitznagel H, Stauss HM, Gohlke P, Zhu YZ, Falkenhahn M, Unger T: Angiotensin II and bradykinin in hypertensive heart disease and myocardial infarction. High Blood Press 1996;5:119–123Google Scholar
  53. 53.
    Zhu YC, Stauss HM, Bao G, Gohlke P, Zhu YZ, Redlich T, Unger T: Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Can J Physiol Pharmacol 1995;73: 827–831PubMedCrossRefGoogle Scholar
  54. 54.
    Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749–756PubMedCrossRefGoogle Scholar
  55. 55.
    Paquet J-L, Baudouin-Legros M, Brunelle G, Meyer P: Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990;8:565–572PubMedCrossRefGoogle Scholar
  56. 56.
    Schelling P, Ganten D, Speck G, Fischer H: Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol 1979;98:503–514PubMedCrossRefGoogle Scholar
  57. 57.
    Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651–657PubMedCrossRefGoogle Scholar
  58. 58.
    Freeman GL, Little WC, Haywood JR: Reduction of left ventricular mass in normal rats by Captopril. Cardiovasc Res 1987;21:323–327PubMedCrossRefGoogle Scholar
  59. 59.
    Nakashima Y, Fouad FM, Tarazi RC: Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984;53:1044–1049PubMedCrossRefGoogle Scholar
  60. 60.
    Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. Am J Hypertens 1992;5:95–110PubMedGoogle Scholar
  61. 61.
    Lievre M, Guéret P, Gayet C, Roudaut R, Haugh MC, Delair S, Boissel J-P, on behalb of the HYCAR Study Group: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995;25:92–97(abstract)PubMedCrossRefGoogle Scholar
  62. 62.
    Fernandez PG, Snedden W, Idikio H, Fernandez D, Kin BK, Triggle CR: The reversal of left ventricular hypertrophy with control of blood pressure in experimental hypertension. Scand J Clin Lab Invest 1984;44:711–716PubMedCrossRefGoogle Scholar
  63. 63.
    Clozel J-P, Hefti F: Cilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1988; 11:568–572PubMedCrossRefGoogle Scholar
  64. 64.
    Linz W, Schölkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exper Hypertens 1989; A11(7): 1325–1350CrossRefGoogle Scholar
  65. 65.
    Rhaleb N-E, Yang X-P, Scicli AG, Carretero OA: Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 1994;23 (part 2):865–868PubMedCrossRefGoogle Scholar
  66. 66.
    Mall G, Zimmer G, Baden S, Mattfeldt T: Capillary neoformation in the rat heart— Stereological studies on papillary muscles in hypertrophy and physiologic growth. Basic Res Cardiol 1990;85:531–540PubMedCrossRefGoogle Scholar
  67. 67.
    Mattfeldt T, Mall G: Growth of capillaries and myocardial cells in the normal rat heart. J Mol Cell Cardiol 1987;19:1237–1246PubMedCrossRefGoogle Scholar
  68. 68.
    Clozel J-P, Kuhn H, Hefti F: Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989;7:267–275PubMedGoogle Scholar
  69. 69.
    Olivetti G, Cigola E, Lagrasta C, Ricci R, Quaini F, Monopoli A, Ongini E: Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993;21:362–370PubMedCrossRefGoogle Scholar
  70. 70.
    Gohlke P, Stoll M, Lamberty V, Mattfeldt T, Mall G, Von Even P, Martorana PA, Unger T: Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. J Hypertens 1992;10(suppl. 6):S141–S144Google Scholar
  71. 71.
    Linz W, Wiemer G, Becker RHA, Schölkens BA: Long-term treatment with the ACE-inhibitor ramipril prolongs survival iri stroke-prone rats: Interim analysis. J Hypertens 1996;14(suppl. 1):S232 (P1055)Google Scholar
  72. 72.
    Wiemer G, Schülkens BA, Busse R, Wagner A, Heitsch H, Linz W: The functional role of angiotensin II —subtype AT2 — receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 1993;3:24–27Google Scholar
  73. 73.
    Seyedi N, Xu XB, Nasjiletti A, Hintze TH: Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164–170PubMedCrossRefGoogle Scholar
  74. 74.
    Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T: Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996;28:397–402PubMedCrossRefGoogle Scholar
  75. 75.
    Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205–251PubMedGoogle Scholar
  76. 76.
    Campbell DJ, Kladis A, Valentijn AJ: Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995;26:233–240PubMedCrossRefGoogle Scholar
  77. 77.
    Metsärinne KP, Stoll M, Gohlke P, Paul M, Unger T: Angiotensin II is antiproliferative for coronary endothelial cells in vitro. Pharm Pharmacol Lett 1992;2:150–152Google Scholar
  78. 78.
    Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT, receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci 1995;92:10663–10667PubMedCrossRefGoogle Scholar
  79. 79.
    Munzenmaier DH, Greene AS: Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996;27(3):760–765PubMedCrossRefGoogle Scholar
  80. 80.
    Schaper W, De Brabander M, Lewi P: DNA synthesis and mitosis in coronary collateral vessels of the dog. Circ Res 1971;28:671–679PubMedCrossRefGoogle Scholar
  81. 81.
    Meiniger C, Granger H: Mechanisms leading to adenosine-stimulated proliferation of microvascular endothelial cells. Am J Physiol 1990;258:H198–H206Google Scholar
  82. 82.
    Quinkler W, Maasberg M, Bernotat-Danielowski S, Lüthe N, Sharma H.S., Schaper W: Isolation of heparin-binding growth factors from bovine, porcine and canine hearts. Eur J Biochem 1989;1989:67–73CrossRefGoogle Scholar
  83. 83.
    Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield L, Heine V, Liotta L, Falanga V, Kehr JH, Fauci AS: Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167–4171PubMedCrossRefGoogle Scholar
  84. 84.
    Casscells W, Speir E, Sasse J, Klagsbrun M, Allen P, Lee M, Calvo B, Chiba M, Haggroth L, Folkman J, Epstein S: Isolation, characterization, and localization of heparin-binding growth factors in the heart. J Clin Invest 1990;85:433–441PubMedCrossRefGoogle Scholar
  85. 85.
    Adair TH, Gay WJ, Montani J-P: Growth regulation of the vascular system: evidence for a metabolic hypothesis. Am J Physiol 1990;259:R393–R404PubMedGoogle Scholar
  86. 86.
    Tschöpe C, Stoll M, Gohlke P, Unger T: Potential effects of bradykinin on myocardial capillary growth after angiotensin converting enzyme inhibition. Exp Opin Invest Drugs 1994;3:501–510CrossRefGoogle Scholar
  87. 87.
    Morbidelli L, Parenti A, Granger HJ, Ziche M, Ledda F: Activation of DNA synthesis and inositol-phosphate turnover in coronary venular endothelial cells exposed to bradykinin. Pharmacol Res 1992;25(Suppl. 2): 150–151CrossRefGoogle Scholar
  88. 88.
    Linz W, Martorana PA, Schölkens BA: Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990;15(suppl. 6):S99–S109PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Peter Gohlke
    • 1
  • Carsten Tschöpe
    • 1
    • 2
  • Thomas Unger
    • 1
  1. 1.Department of PharmacologyUniversity of KielKielGermany
  2. 2.Department of Cardiology and PneumologyUniversiy Hospital Benjamin Franklin Free University of BerlinBerlinGermany

Personalised recommendations